ProfileGDS5678 / 1420915_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 74% 74% 74% 94% 80% 75% 75% 74% 76% 74% 72% 74% 74% 71% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.8377974
GSM967853U87-EV human glioblastoma xenograft - Control 24.8786874
GSM967854U87-EV human glioblastoma xenograft - Control 34.8071974
GSM967855U87-EV human glioblastoma xenograft - Control 48.3177394
GSM967856U87-EV human glioblastoma xenograft - Control 55.648480
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.8437675
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.8345175
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.8206874
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.1375876
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.8345174
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.5747672
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.8356574
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.8382374
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.4610371